COMPREHENSIVE
PRE-ECLAMPSIA
MANAGEMENT
FOR ALL TRIMESTERS
Pre-eclampsia screening in the
1st trimester
PerkinElmer has over 30 years of experience in prenatal
testing and our comprehensive offering includes a test for
assessing the risk of early pre-eclampsia, PlGF 1-2-3
™
.
The multinational ASPRE study showed that a combined
pre-eclampsia screening program in the first trimester
of pregnancy (11-13+6) , together with 150mg Aspirin
treatment to high risk patients decrease the incidence of
preterm pre-eclampsia (requiring delivery < 37 weeks) by
62%. The treatment, started after the screening to women
at high risk, can help prevent major part of the preterm pre-
eclampsia cases. [1].
PerkinElmer does not endorse or make recommendations with respect to research, medication, or treatments. All
information presented is for informational purposes only and is not intended as medical advice. For country specific
recommendations, please consult your local health care professionals.
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please
check with your local representative for availability.
[1]
ASPRE trial: performance of screening for preterm pre-eclampsia. Rolnik DL,Wright D, Poon LCY, Syngelaki A,
O’Gorman N, de Paco Matallana C,Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W,
Papaioannou G,Tenenbaum-Gavish K, Nicolaides KH.
DOPPLER
ULTRASOUND
BLOOD PRESSURE
MEASUREMENT
BLOOD TEST
PIGF 1-2-3
™
BLOOD TEST
sFlt-1 &
PlGF 1-2-3
™
MEDICAL
HISTORY
CLINICAL
SYMPTOMS
More information about pre-eclampsia prediction and
management during pregnancy:
prenataltesting.perkinelmer.com
Pre-eclampsia management in the
2nd & 3rd trimester
We also offer DELFIA® Xpress sFlt-1 kit for pre-eclampsia
testing in the 2nd and 3rd trimester of pregnancy.
sFlt-1/PlGF ratio can be used to aid in diagnosis and to
monitor the development of pre-eclampsia together with
symptoms and other clinical findings.
The sFlt-1/PlGF ratio that is measured and analyzed from a
blood sample with the DELFIA® Xpress instrument can be
used for follow up to identify women with pre-eclampsia,
thus aiding make decisions about the course of care, and to
avoid unnecessary hospitalization.
